USPSTF Recommends Depression Screening, Anxiety Screening
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, June 20, 2023 -- The U.S. Preventive Services Task Force (USPSTF) recommends depression screening for all adults and anxiety screening for younger adults, but the evidence is insufficient for recommending screening for suicide risk in all adults or for anxiety screening in older adults. These findings form the basis of two final recommendation statements published in the June 20 issue of the Journal of the American Medical Association.
Elizabeth A. O'Connor, Ph.D., from the Kaiser Permanente Evidence-based Practice Center in Portland, Oregon, and colleagues reviewed the benefits and harms of screening and treatment for depression and suicide risk among adult primary care patients using data from 105 studies. The researchers found that depression screening interventions were associated with a lower prevalence of depression or clinically important depressive symptomatology after six to 12 months (pooled odds ratio, 0.60). A large body of evidence supported the benefits of psychological and pharmacologic depression treatment. There was generally no improvement over usual care in the included suicide prevention studies. Based on these findings, the USPSTF concludes that screening for major depressive disorder in adults has moderate net benefit (B statement), while the evidence is insufficient for assessing the benefits and harms of screening for suicide risk (I statement).
In a second evidence review, O'Connor and colleagues reviewed the benefits and harms of screening and treatment for anxiety among primary care patients using data from 59 publications. The researchers found that in two screening studies, there was no benefit for anxiety screening. Treatment for anxiety was supported by a large body of evidence. Based on these findings, the USPSTF concludes that anxiety disorder screening among adults had a moderate net benefit (B statement), but the evidence is insufficient for screening older adults (age 65 years or older; I statement).
"We are urgently calling for more research to determine the effectiveness of screening all adults for suicide risk and screening adults 65 and older for anxiety disorders," task force member Gbenga Ogedegbe, M.D., M.P.H., said in a statement.
Final Recommendation Statement - Depression and Suicide
Evidence Report - Depression and Suicide
Final Recommendation Statement - Anxiety
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Risk of Suicide, Homicide Both Higher at Night
FRIDAY, June 7, 2024 -- The risk of suicide and homicide is higher at night than might be expected based on the number of people awake at that time, according to a study published...
Social Media Use Tied to Depression, but Not Sole Cause in Young Adults
FRIDAY, June 7, 2024 -- Social media use and depression are associated, but social media use is not prospectively related to the course of depressive symptoms, according to a...
Many Patients Have Discontinuation Symptoms After Stopping Antidepressants
THURSDAY, June 6, 2024 -- A considerable proportion of patients have discontinuation symptoms (e.g., dizziness, headache, nausea, insomnia, and irritability) after...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.